Literature DB >> 29472353

Long-term management of leukocyte adhesion deficiency type III without hematopoietic stem cell transplantation.

Paul Saultier1,2, Sarah Szepetowski3, Matthias Canault2, Céline Falaise3,4,5, Marjorie Poggi2, Pierre Suchon2,4, Vincent Barlogis3,6, Gérard Michel3,6, Stéphane Loyau7, Martine Jandrot-Perrus7, Jean-Claude Bordet8,9, Marie-Christine Alessi2,4,5, Hervé Chambost3,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29472353      PMCID： PMC6058776          DOI： 10.3324/haematol.2017.186304

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Leukocyte adhesion deficiency type 1 (LAD-1)/variant. A novel immunodeficiency syndrome characterized by dysfunctional beta2 integrins.

Authors:  T W Kuijpers; R A Van Lier; D Hamann; M de Boer; L Y Thung; R S Weening; A J Verhoeven; D Roos
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

2.  Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation.

Authors:  Elmina Mammadova-Bach; Véronique Ollivier; Stéphane Loyau; Mathieu Schaff; Bénédicte Dumont; Rémi Favier; Geneviève Freyburger; Véronique Latger-Cannard; Bernhard Nieswandt; Christian Gachet; Pierre H Mangin; Martine Jandrot-Perrus
Journal:  Blood       Date:  2015-05-14       Impact factor: 22.113

Review 3.  Leukocyte adhesion deficiency III - when integrins activation fails.

Authors:  Amos Etzioni
Journal:  J Clin Immunol       Date:  2014-09-20       Impact factor: 8.317

Review 4.  Reduced-intensity conditioning for allogeneic stem cell transplant in primary immune deficiencies.

Authors:  Robert Chiesa; Paul Veys
Journal:  Expert Rev Clin Immunol       Date:  2012-03       Impact factor: 4.473

5.  Natural history and early diagnosis of LAD-1/variant syndrome.

Authors:  Taco W Kuijpers; Robin van Bruggen; Nanne Kamerbeek; Anton T J Tool; Gonul Hicsonmez; Aytemiz Gurgey; Axel Karow; Arthur J Verhoeven; Karl Seeger; Ozden Sanal; Charlotte Niemeyer; Dirk Roos
Journal:  Blood       Date:  2006-12-21       Impact factor: 22.113

6.  Adaptive immune defects in a patient with leukocyte adhesion deficiency type III with a novel mutation in FERMT3.

Authors:  Narissara Suratannon; Patra Yeetong; Chalurmpon Srichomthong; Pramuk Amarinthnukrowh; Pantipa Chatchatee; Darintr Sosothikul; P Martin van Hagen; Mirjam van der Burg; Marjolein Wentink; Gertjan J Driessen; Kanya Suphapeetiporn; Vorasuk Shotelersuk
Journal:  Pediatr Allergy Immunol       Date:  2015-10-22       Impact factor: 6.377

Review 7.  Eptacog alfa activated: a recombinant product to treat rare congenital bleeding disorders.

Authors:  Giovanni Di Minno
Journal:  Blood Rev       Date:  2015-06       Impact factor: 8.250

Review 8.  New Insights Into the Treatment of Glanzmann Thrombasthenia.

Authors:  Man-Chiu Poon; Giovanni Di Minno; Roseline d'Oiron; Rainer Zotz
Journal:  Transfus Med Rev       Date:  2016-01-30

9.  LAD-1/variant syndrome is caused by mutations in FERMT3.

Authors:  Taco W Kuijpers; Edith van de Vijver; Marian A J Weterman; Martin de Boer; Anton T J Tool; Timo K van den Berg; Markus Moser; Marja E Jakobs; Karl Seeger; Ozden Sanal; Sule Unal; Mualla Cetin; Dirk Roos; Arthur J Verhoeven; Frank Baas
Journal:  Blood       Date:  2008-12-08       Impact factor: 22.113

10.  Macrothrombocytopenia and dense granule deficiency associated with FLI1 variants: ultrastructural and pathogenic features.

Authors:  Paul Saultier; Léa Vidal; Matthias Canault; Denis Bernot; Céline Falaise; Catherine Pouymayou; Jean-Claude Bordet; Noémie Saut; Agathe Rostan; Véronique Baccini; Franck Peiretti; Marie Favier; Pauline Lucca; Jean-François Deleuze; Robert Olaso; Anne Boland; Pierre Emmanuel Morange; Christian Gachet; Fabrice Malergue; Sixtine Fauré; Anita Eckly; David-Alexandre Trégouët; Marjorie Poggi; Marie-Christine Alessi
Journal:  Haematologica       Date:  2017-03-02       Impact factor: 9.941
View more
  5 in total

1.  Allogeneic hematopoietic stem cell transplantation in leukocyte adhesion deficiency type I and III.

Authors:  Shahrzad Bakhtiar; Emilia Salzmann-Manrique; Henric-Jan Blok; Dirk-Jan Eikema; Sheree Hazelaar; Mouhab Ayas; Amos Toren; Gal Goldstein; Despina Moshous; Franco Locatelli; Pietro Merli; Gerard Michel; Gülyüz Öztürk; Ansgar Schulz; Carsten Heilmann; Marianne Ifversen; Rob F Wynn; Olga Aleinikova; Yves Bertrand; Abdelghani Tbakhi; Paul Veys; Musa Karakukcu; Alphan Kupesiz; Ardeshir Ghavamzadeh; Rupert Handgretinger; Emel Unal; Antonio Perez-Martinez; Muge Gokce; Fulvio Porta; Tekin Aksu; Gülsün Karasu; Isabel Badell; Per Ljungman; Elena Skorobogatova; Akif Yesilipek; Tsila Zuckerman; Robbert R G Bredius; Polina Stepensky; Bella Shadur; Mary Slatter; Andrew R Gennery; Michael H Albert; Peter Bader; Arjan Lankester
Journal:  Blood Adv       Date:  2021-01-12

Review 2.  Beta2-Integrins and Interacting Proteins in Leukocyte Trafficking, Immune Suppression, and Immunodeficiency Disease.

Authors:  Susanna C Fagerholm; Carla Guenther; Marc Llort Asens; Terhi Savinko; Liisa M Uotila
Journal:  Front Immunol       Date:  2019-02-19       Impact factor: 7.561

3.  The Impact of Integrin β2 on Granulocyte/Macrophage Progenitor Proliferation.

Authors:  Li-Jie Zhang; Cen Yan; Sarah Schouteden; Xiao-Juan Ma; Dong Zhao; Thorsten Peters; Catherine M Verfaillie; Ying-Mei Feng
Journal:  Stem Cells       Date:  2019-02-07       Impact factor: 6.277

Review 4.  β2 Integrins-Multi-Functional Leukocyte Receptors in Health and Disease.

Authors:  Monika Bednarczyk; Henner Stege; Stephan Grabbe; Matthias Bros
Journal:  Int J Mol Sci       Date:  2020-02-19       Impact factor: 5.923

Review 5.  Higher Incidence of B Cell Malignancies in Primary Immunodeficiencies: A Combination of Intrinsic Genomic Instability and Exocytosis Defects at the Immunological Synapse.

Authors:  Jérôme Mastio; Mezida B Saeed; Hannah Wurzer; Max Krecke; Lisa S Westerberg; Clément Thomas
Journal:  Front Immunol       Date:  2020-11-09       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.